ATRX and central nervous system cancer: Analysis of immunohistochemical indices and IDH1 mutation results showed no differences in GFAP, Olig-2, P53, ATRX, H3K227ME3, FuBP1, BRAFV600E, and Nestin between glioma patients with and without pre-operative seizures (Table 2).